Topic

Illinois

A collection of 499 issues

How to Get Besponsa (Inotuzumab Ozogamicin) Covered by UnitedHealthcare in Illinois: Prior Authorization, Appeals, and State Protections

Quick Answer: Getting Besponsa Covered in Illinois UnitedHealthcare requires prior authorization for Besponsa (inotuzumab ozogamicin) across all Illinois plans. To get approved: (1) Submit PA through UHC Provider Portal with CD22+ lab results and documented failure of standard therapies, (2) Request step therapy exception citing Illinois law 215 ILCS 134/
6 min read

How to Get Myalept (metreleptin) Covered by UnitedHealthcare in Illinois: Complete PA Guide & Appeal Scripts

Answer Box: Getting Myalept (metreleptin) Covered by UnitedHealthcare in Illinois UnitedHealthcare requires prior authorization for Myalept (metreleptin) with specific criteria for generalized lipodystrophy. No step therapy applies since there are no therapeutic alternatives. To get approved: (1) Confirm your endocrinologist is REMS-certified, (2) Submit PA with diagnosis documentation and metabolic
5 min read

Work With Your Doctor to Get Brineura (cerliponase alfa) Approved by UnitedHealthcare in Illinois: Complete Provider Collaboration Guide

Answer Box: Getting Brineura Approved in Illinois To get Brineura (cerliponase alfa) covered by UnitedHealthcare in Illinois, you need: confirmed CLN2 diagnosis by a pediatric neurologist, motor function score ≥1 on the CLN2 Clinical Rating Scale, and administration at a qualified center. Your first step today: Schedule with your child&
7 min read

How to Get Mepsevii (vestronidase alfa-vjbk) Covered by UnitedHealthcare in Illinois: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Mepsevii Covered in Illinois UnitedHealthcare requires prior authorization for Mepsevii (vestronidase alfa-vjbk) across all plans in Illinois. Submit via the OptumRx Provider Portal with confirmed MPS VII diagnosis (β-glucuronidase enzyme assay or GUSB genetic testing), specialist documentation, and patient weight for dosing. Processing takes 5-15 business days.
6 min read

Helixate (Antihemophilic Factor, rFVIII) Coverage with Blue Cross Blue Shield in Illinois: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Helixate Covered in Illinois Important: Helixate NexGen and Kogenate FS have been permanently discontinued by Bayer. Blue Cross Blue Shield of Illinois (BCBSIL) now requires prior authorization for alternative factor VIII products like Kovaltry, Jivi, or Advate. To get coverage: (1) Work with your hematologist to select
6 min read

How to Get Cabometyx (cabozantinib) Covered by Cigna in Illinois: Complete Prior Authorization and Appeals Guide

Quick Answer: Cabometyx Coverage by Cigna in Illinois Cabometyx (cabozantinib tablets) requires prior authorization from Cigna in Illinois. Your fastest path to approval: (1) Confirm you meet Cigna's diagnosis-specific criteria (hepatocellular carcinoma with prior systemic therapy, or differentiated thyroid carcinoma age 12+), (2) Have your prescriber submit via
5 min read

How to Get Cometriq (Cabozantinib) Covered by Aetna CVS Health in Illinois: Prior Authorization Guide and Appeals Process

Answer Box: Getting Cometriq Covered by Aetna CVS Health in Illinois Cometriq (cabozantinib) requires prior authorization from Aetna CVS Health for medullary thyroid carcinoma (MTC) coverage. Submit your PA request via the Availity provider portal or fax to 1-888-267-3277 with oncologist attestation, confirmed MTC diagnosis, and documentation of disease progression.
5 min read

The Complete Guide to Getting Uplizna (Inebilizumab) Covered by UnitedHealthcare in Illinois: Requirements, Appeals, and Forms

Answer Box: Getting Uplizna Covered by UnitedHealthcare in Illinois UnitedHealthcare requires prior authorization for Uplizna (inebilizumab) with step therapy requirements. The fastest path to approval: 1) Verify your plan covers J-code J1823 under medical benefits, 2) Submit prior authorization through the UnitedHealthcare Provider Portal with AQP4-IgG positive test results (for
6 min read